Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.1.3.9 (glucose-6-phosphatase)
 3,081 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We have described a 20-month-old child with type IB glycogen storage disease, based on clinical and biochemical manifestations. Functional testing data were similar to those found in glucose-6-phosphatase deficiency, but in vitro studies showed normal hepatic glucose-6-phosphatase activity. Disruption of membranes with deoxycholic acid was followed by an increase in enzyme activity compared to a control liver tissue, suggesting "latency" of enzyme. We suggest that this patient had glycogen storage type IB and that this disorder may represent a specific glucose-6-phosphate transport defect.
 ...
PMID:Glycogenosis type IB: possible membrane transport defect. 626 32

A new variant of glycogen storage disease (GSD) Type 1, with clinical symptoms and laboratory findings consistent with those of glucose-6-phosphatase (G6Pase) deficiency, is described. Assay of G6Pase in liver from the patient immediately after biopsy by the method of Nordlie and Arion gave low activity (0.8 mumol/min per g liver) in the absence of detergent, but was normal (10.2 mumol/min per g liver) after addition of detergent. Liver stored for a day at -25 degrees C had normal activity (3.4 mumol/min per g liver) without detergent. In patients with GSD Type la, G6Pase activity was very low both with and without detergent. These findings suggest a defect in glucose-6-phosphate transport in the microsomal membrane of the patient's liver. The integrity of microsomal membrane was destroyed by storage at -25 degrees C, when activity of G6 ase in the patient's liver could be demonstrated. This may be the first example of a disorder involving the transport system of an intracellular membrane.
 ...
PMID:A new variant of glycogen storage disease type 1: probably due to a defect in the glucose-6-phosphate transport system. 627 50

The availability of a fresh, unfrozen liver biopsy specimen permitted the characterization of a unique type of glycogen storage disease. The subject, an 11-year-old female, showed the classic clinical symptoms of type I glycogenosis. However, her hepatic D-glucose-6-phosphate phosphohydrolase (EC 3.1.3.9) level as determined with detergent-activated homogenate was normal. The underlying mechanism was studied with intact microsomes from this fresh liver homogenate. Glucose-6-P phosphohydrolase was 75% latent, compared with 25% in normal controls matched for age and sex. Inorganic pyrophosphatase, PPi:glucose phosphotransferase, and carbamyl-P:glucose phosphotransferase activities of glucose 6-phosphatase were totally latent. While not observed with intact microsomes, these activities were fully manifested with detergent-disrupted microsomes. D-Glucose inhibited glucose-6-P phosphohydrolase activity of both intact and disrupted microsomes, but exogenous Pi inhibited only with the detergent-disrupted preparation. These observations are interpreted on the basis of the multicomponent glucose 6-phosphatase system of Arion et al. (Arion, W. J., Lange, A. J., Walls, H. E., and Ballas, L. M. (1980) J. Biol. Chem. 255, 10396-10406). All are consistent with a defect in T2, the putative translocase specific for Pi, PPi, and carbamyl-P. However, Pi produced endogenously from glucose-6-P hydrolysis within the microsomal lumen did not inhibit. This suggests that (i) a pathway for egress of Pi from the microsomal lumen exists independently of T2, (ii) T2 in this case works only unidirectionally, or (iii) the catalytic unit of glucose 6-phosphatase in situ has become desensitized to interactions with Pi, PPi, and carbamyl-P in this mutant model. Defects in both T1, the translocase specific for glucose-6-P, and T2 thus appear involved in this unique glycogenosis.
 ...
PMID:Type Ic, a novel glycogenosis. Underlying mechanism. 630 84

Glycogen storage disease type Ib has all the clinical manifestations of glycogen storage disease type Ia such as hepatomegaly, growth retardation, bleeding tendency, hypoglycemia, hyperlactacidemia, hyperuricemia, hyperlipidemia, impaired platelet function plus neutropenia. The overall glucose-6-phosphatase activity in disrupted microsomes from liver is normal whereas glucose-6-phosphate translocase, the first enzyme in the glucose-6-phosphate transport system is absent. There is no glucose-6-phosphatase activity in vivo. Recent results show that in granulocytes the glucose-6-phosphate-dependent hexosemonophosphate-shunt is impaired.
 ...
PMID:Glycogen storage disease type Ib. 631 72

The most commonly recognized type of glycogen storage disease (von Gierke's disease) results from deficient glucose-6-phosphatase activity. This enzyme is the last step in the release of free glucose from the liver into the circulation. Thus, the most prominent and life-threatening complication in the illness is severe and often prolonged hypoglycemia, which occurs after the dietary glucose is normally removed from the circulation. With an optimal dietary intake spaced at 2 1/2- to 3 1/2-hour intervals, the blood glucose can be maintained in the normal range during the daytime, but hypoglycemia may occur during overnight fasting. Recent advances in the understanding of the pathophysiology of the illness have led to the use of frequent high-starch feedings during the day and nocturnal intragastric infusions of liquid formulas containing glucose polymers. The liquid formula is infused through either a nasogastric or a gastrostomy tube continuously at night while the patient sleeps. The success of this treatment not only has improved the survival rate but also has corrected the abnormal blood chemistries and generated a more normal rate of growth and development. Because patients with this disease are reaching adulthood in greater numbers, it is necessary for dietitians caring for adults as well as for children to become familiar with the prescribed methods of treatment.
 ...
PMID:Dietary management of Type I glycogen storage disease. 658 74

The main substrates for brain energy metabolism were measured in blood samples taken from the carotid artery and the internal jugular bulb of four children with glycogen storage disease caused by deficiency of glucose-6-phosphatase. Multiple paired arterial and venous blood samples were analyzed for glucose, lactate, pyruvate, D-beta-hydroxybutyrate, acetoacetate, glycerol and O2, and the arteriovenous differences of the concentrations were calculated. In the first three patients the substrates were measured in two successive conditions with lower and higher glucose-intake, respectively, inducing reciprocally higher and lower concentrations of blood lactate. In the fourth patient medium chain triglycerides were administered simultaneously with the glucose-containing gastric drip feeding. Lactate appeared to be taken up significantly. It consumed, if completely oxidized, between 40-50% of the total O2 uptake in most cases. Only once in one patient the uptake of lactate switched to its release, when the blood lactate level decreased to normal. D-beta-hydroxybutyrate and acetoacetate arteriovenous (A-V) differences were small to negligible and these ketone bodies, therefore, did not contribute substantially to the brain's energy expenditure. Glycerol was not metabolized by the brain. Lactate thus appeared to be the second brain fuel next to glucose. It may protect the brain against fuel depletion in case of hypoglycemia.
 ...
PMID:Lactate as a cerebral metabolic fuel for glucose-6-phosphatase deficient children. 658 74

Systematic studies of the sequence of cellular changes during hepatocarcinogenesis induced predominantly in rats by stop experiments with N-nitrosomorpholine (NNM) led to the following main results and conclusions: The development of hepatocellular tumors is preceded by a multifocal hepatic glycogen storage disease (glycogenosis). Cytomorphological and cytochemical findings suggest a sequence of focal changes leading from clear and acidophilic glycogen storage foci through mixed cell foci and neoplastic nodules to hepatocellular carcinomas. The clear and acidophilic glycogen storage cells persisting after withdrawal of the carcinogen apparently represent a preneoplastic cell population, the neoplastic transformation of which is accompanied by a gradual reduction of glycogen and a concomitant increase in ribosomes (basophilia). The first appearance and frequency of the different liver lesions investigated was shown to depend on the dose of carcinogen administered. With increasing dose of NNM, the number of focal lesions considerably increased, and this was accompanied by an earlier development of mixed and basophilic cell populations. There was no indication of any reversibility of pronounced focal lesions under the experimental conditions chosen. On the contrary, the foci became larger and acquired phenotypic markers closer to neoplasia independent of further action of the carcinogen. Enzyme histochemically, the majority of the pronounced glycogen storage foci showed a reduction in the activities of glycogen phosphorylase and glucose-6-phosphatase while the activity of glucose-6-phosphate dehydrogenase, a key enzyme for the pentose phosphate pathway, was increased. The mixed cell foci, neoplastic nodules and carcinomas which emerged at later stages were characterized by a progressive shift away from glycogen metabolism towards glycolysis and the pentose phosphate pathway. as indicated by an increase in glyceraldehyde-3-phosphate dehydrogenase and glucose-6-phosphate dehydrogenase activities. These changes in enzyme pattern are in keeping with a developmental sequence leading from glycogen storage foci through mixed cell foci and neoplastic nodules to hepatocellular carcinomas. Biochemical microanalysis of dissected glycogen storage foci and mixed cell foci revealed that the foci composed exclusively of storage cells contained on an average 100% more glycogen than the normal liver tissue. The overall glycogen content of the mixed cell foci, which were composed of both glycogenotic and glycogen-poor basophilic cells, was not distinguishable from that of normal tissue.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:Hepatocellular glycogenosis and related pattern of enzymatic changes during hepatocarcinogenesis. 659 71

Type IB Glycogen storage disease (GSD) is a new variant of type I Glycogen storage disease. It is characterized by same clinical findings: hepatomegaly, fasting hypoglycemia, hyperlipidemia, hyperuricemia, lactic acidosis, renal enlargement, short stature; but it distinguish for normal glucose-6-phosphatase hepatic activity in vitro. The involvement is in G-6-P transport system. Recently has been described in some patients with GSD IB, neutropenia and defective neutrophil mobility. In this report the authors described two family cases of GDS IB that one characterized by severe neutropenia.
 ...
PMID:[Neutropenia in glycogenesis I B]. 659 20

Continuous nocturnal intragastric feeding, combined with frequent daytime feedings, has been reported to improve both linear growth and the metabolic abnormalities in patients with glucose-6-phosphatase deficiency (Type I Glycogen Storage Disease). However, elevated blood levels of lactate have persisted. The present studies explore the relationship between blood lactate concentrations in six patients with glucose-6-phosphatase deficiency and variations in the rate and composition of the intragastric feeding. Blood lactate and plasma glucose concentrations were determined at rates of dextrose administration ranging from 3-34 mg/kg/min. Dextrose infusion at 100-200% of estimated normal glucose production rates gave the best control of blood lactate concentrations. Lower rates of dextrose infusion resulted in significantly higher blood lactate levels; higher rates produced hyperglycemia, but no significant further reduction of blood lactate. At identical rates of glucose administration, a dextrose-containing infant formula and a high carbohydrate enteric feeding solution gave no significant improvement in control of blood lactate levels compared to dextrose alone. Plasma glucose levels fell more rapidly when intragastric feeding was stopped than after a mixed meal and hypoglycemia appeared to develop before counter-regulatory responses could be mobilized. These observations may account for the increased susceptibility to symptomatic hypoglycemia reported in patients treated with intragastric feeding.
 ...
PMID:Intragastric feeding in type I glycogen storage disease: factors affecting the control of lactic acidemia. 679 37

A 4.5 months old girl was suspected to have Glycogenosis type I because of hepatomegalie and recurrent hypoglycemia. Liverbiopsy revealed a normal glycogen content and a normal in vitro activity of glucose-6-phosphatase. We then examined the carbohydrate metabolism and could demonstrate that in vitro the transfer of glucose-6-phosphate to glucose was blocked. We therefore conclude that a normal in vitro activity of glucose-6-phosphatase does not rule out the diagnosis of Glycogenosis type I. Evaluation of carbohydrate metabolism is an important tool in marking the diagnosis. We suggest to use the term Glycogenosis type I B, which some institutions already use for this disorder.
 ...
PMID:[Glycogen storage disease type I with normal in vitro activity of glucose-6-phosphatase (author's transl)]. 693 85


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>